1Burchill SA. Ewing's sarcorna: Diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Patho, 2003, 56 ( 2 ):296-302.
2Soderstrom M, Bohling T, Ekfors T. et al. Molecular profiling of human chondrosarcomas for matrix production and cancer markers. Int J Cancer,2002,100(2): 144-151.
3Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma on coprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell, 2002,1 (4): 393-401.
4Rutherford J, Chu CE, Duddy PM, et al. Investigations on a clinically and functionally unusual and novel germline p53 mutation. Br J Cancer,2002,86(10) :1592-1596.
5Hemmati PG, Gillissen B, Von Haefen C, et al. Adenovirus-mediated overexpression of p14 (ARF) induces p53 and Bax-independent apoptosis. Oncogene,2002,21 (20) :3149-3161.
6Dagher R,Long LM,Read EJ ,et al. Pilot trial of tumour-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing's sarcoma and alveolar rhabdomyosarcoma: An interinstitute NIH study. Med Pediatr Oncol, 2002,38 (3): 158-164.
7Luksch R, Massimino M, Cefalo G, et al. Effects of recombinant human granulocyte-macrophage colony-srimulating factor in an intensive treatment program for children with Ewing's sarcoma. Haematol, 2001,86(7): 753-760.
8Torricelli P, Montanari N, Spina V, et al. Dynamic contrast enhanced magnetic resonance imaging subtraction in evaliating osteosarcoma re sponse to chemotherapy. Radio Med (Torino), 2001, 101 (3): 145-151.
9Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumour of bone. N Engl J Med, 2003,348 (8): 694-701.
10Bacci G,Mercuri M, Longhi A, et al. Neoadjuvant chemotherapy for Ewing's tumour of bone: Recent experience at the Rizzoli Orthopaedic Institute. Eur J Cancer, 2002,38 (17): 2243-2251.
